Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.42 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.39 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10704431 | 0.81 | KDM4E (0.45) | NPC1MTORKDM4EALDH1A1GLA | |
| SCHEMBL3519703 | 0.75 | MAP2K4 (0.50) | ALDH1A1HPGDCDK5 | |
| SCHEMBL3523207 | 0.75 | PDE3B (0.58) | NPC1MTORKDM4EALDH1A1HPGD | |
| SCHEMBL3519897 | 0.72 | MAP2K4 (0.47) | KDM4EALDH1A1CDK5 | |
| SCHEMBL10704493 | 0.71 | CA2 (0.49) | CA2MAPK10RIPK1KDM4EHPGD | |
| SCHEMBL11876463 | 0.71 | RPS6KB2 (0.56) | NPC1MTORKDM4EALDH1A1GLA | |
| SCHEMBL21479878 | 0.70 | MAPK10 (0.45) | MAPK10RIPK1NPC1MTORKDM4E | |
| SCHEMBL15918659 | 0.69 | KDM4E (0.47) | NPC1MTORKDM4EALDH1A1GLA | |
| SCHEMBL11863735 | 0.68 | CDK5 (0.47) | NPC1MTORKDM4EALDH1A1GLA | |
| SCHEMBL12322576 | 0.67 | MAT2A (0.60) | CA2KDM4EHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240065302-A1 | SWEETENER COMPOSITIONS COMPRISING MOGROSIDES AND USES THEREOF | FIRMENICH INCORPORATED | 2024-02-29 | — | — | US | disclosed |
| EP-2573559-B1 | Modulation of chemosensory receptors and ligands associated therewith | SENOMYX INC (US) | 2019-03-13 | — | — | EP | disclosed |
| EP-2573559-B1 | Modulation of chemosensory receptors and ligands associated therewith | SENOMYX INC (US) | 2019-03-13 | — | — | EP | disclosed |
| US-20180086751-A1 | SWEETENER COMPOSITION | SENOMYX, INC. | 2018-03-29 | — | — | US | disclosed |
| US-20180086751-A1 | SWEETENER COMPOSITION | SENOMYX, INC. | 2018-03-29 | — | — | US | disclosed |
| EP-2062050-B1 | MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH | SENOMYX INC (US) | 2016-05-18 | — | — | EP | disclosed |
| EP-2062050-B1 | MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH | SENOMYX INC (US) | 2016-05-18 | — | — | EP | disclosed |
| US-9181276-B2 | Modulation of chemosensory receptors and ligands associated therewith | SENOMYX, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-9181276-B2 | Modulation of chemosensory receptors and ligands associated therewith | SENOMYX, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-9181276-B2 | Modulation of chemosensory receptors and ligands associated therewith | SENOMYX, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20110224155-A1 | MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH | SENOMYX INC. (US) | 2011-09-15 | — | — | US | disclosed |
| US-20110224155-A1 | MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH | SENOMYX INC. (US) | 2011-09-15 | — | — | US | disclosed |
| US-20110224155-A1 | MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH | SENOMYX INC. (US) | 2011-09-15 | — | — | US | disclosed |
| US-7928111-B2 | Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors | SENOMYX, INC. (US) | 2011-04-19 | — | — | US | disclosed |
| US-7928111-B2 | Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors | SENOMYX, INC. (US) | 2011-04-19 | — | — | US | disclosed |
| US-7928111-B2 | Compounds including substituted thienopyrimidinone derivatives as ligands for modulating chemosensory receptors | SENOMYX, INC. (US) | 2011-04-19 | — | — | US | disclosed |
| WO-2008154221-A2 | MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH | SENOMYX, INC. (US) | 2008-12-18 | — | — | WO | disclosed |
| US-20080306053-A1 | MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH | SENOMYX, INC. (US) | 2008-12-11 | — | — | US | disclosed |
| US-20080306053-A1 | MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH | SENOMYX, INC. (US) | 2008-12-11 | — | — | US | disclosed |
| US-20080306053-A1 | MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH | SENOMYX, INC. (US) | 2008-12-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180086751-A1 | SWEETENER COMPOSITION | TAS2R50, TAS1R2, TAS2R10 | CA2 3146/4885MAPK10 3053/4885RIPK1 3084/4885 |
| US-20080306053-A1 | MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH | OR51E2, TAS2R50, TAS2R30 | CA2 3119/4885MAPK10 1532/4885RIPK1 916/4885 |
| US-20110224155-A1 | MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH | TAS2R30, TAS2R50, TAS2R1 | CA2 1990/4885MAPK10 2361/4885RIPK1 369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.